<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11336467</article-id><article-id pub-id-type="pmc">2363882</article-id><article-id pub-id-type="pii">6691784</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1784</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Douillard</surname><given-names>J Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lerouge</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Monnier</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bennouna</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haller</surname><given-names>A M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>X S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Assouline</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Grau</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rivi&#x000e8;re</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Centre Ren&#x000e9; Gauducheau, 44805 Saint-Herblain, France</aff><aff id="aff2"><label>2</label>Centre Fran&#x000e7;ois Baclesse, 14076 Caen, France</aff><aff id="aff3"><label>3</label>C.H.G Andr&#x000e9; Boulloche, 25209 Montbeliard, France</aff><aff id="aff4"><label>4</label>C.H.U. de Nancy H&#x000f4;pital de Brabois, 54511 Vandoeuvre, France</aff><aff id="aff5"><label>5</label>Clinique du Mail, 38034 Grenoble, France</aff><aff id="aff6"><label>6</label>Bristol-Myers Squibb, 92044 Paris la D&#x000e9;fense, France</aff><pub-date pub-type="ppub"><month>05</month><year>2001</year></pub-date><volume>84</volume><issue>9</issue><fpage>1179</fpage><lpage>1184</lpage><history><date date-type="received"><day>02</day><month>10</month><year>2000</year></date><date date-type="rev-recd"><day>14</day><month>02</month><year>2001</year></date><date date-type="accepted"><day>20</day><month>02</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000&#x02008;mg/m<sup>2</sup>was administered on days 1 and 8 and paclitaxel 200&#x02008;mg/m<sup>2</sup>as a continuous 3-hour infusion on day 1. Treatment was repeated every 21 days. Patients had a median age of 53 years. ECOG performance status was 0 or 1 in 48 patients. 41 patients (75.9&#x00025;) had initial stage IV disease; histology was mainly adenocarcinoma (46.3&#x00025;). 2 patients (4.3&#x00025;) achieved a complete response and 15 (31.9&#x00025;) achieved a partial response giving an overall response rate of 36.2&#x00025; (95&#x00025; CI: 22.4&#x02013;49.9&#x00025;); 19 patients (40.4&#x00025;) had stable disease and 10 (21.3&#x00025;) had progressive disease. The median survival time was 51 weeks (95&#x00025; CI: 46.5&#x02013;59.3), with a 1-year survival probability of 0.48 (95&#x00025; CI: 0.34&#x02013;0.63). Grade 3/4 neutropenia and febrile neutropenia occurred in 15.2&#x00025; and 2.2&#x00025; of courses, respectively. Grade 3/4 thrombocytopenia was rare (1.8&#x00025; of courses). Peripheral neurotoxicity developed in 25 patients (47.2&#x00025;), mostly grade 1/2. Arthalgia/myalgia was observed in 30 patients (56.6&#x00025;), generally grade 1 or 2. Grade 3 abnormal levels of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) occurred in 5 patients (9.4&#x00025;) and 1 patient (1.9&#x00025;), respectively. Combined paclitaxel and gemcitabine is an active and well-tolerated regimen for the treatment of advanced NSCLC, and warrants further investigation in comparative, randomized trials. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>gemcitabine</kwd><kwd>chemotherapy</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front></article>


